Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
14 avr. 2022 08h30 HE
|
Celsion Corporation
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting LAWRENCEVILLE, N.J., April 14, 2022 (GLOBE NEWSWIRE) --...
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
12 avr. 2022 08h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS
11 avr. 2022 10h00 HE
|
Invectys, Inc.
Houston, Texas, USA, April 11, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company which is developing a next generation of therapies to meet the needs...
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
01 avr. 2022 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
17 sept. 2021 09h00 HE
|
Celsion CORP
Expands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J. and HAINAN, China, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
Celsion Appoints Christine A. Pellizzari to its Board of Directors
09 juin 2021 08h00 HE
|
Celsion CORP
Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J., June 09, 2021 (GLOBE...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
25 mai 2021 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
13 mai 2021 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
11 mai 2021 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses
11 mai 2021 08h00 HE
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J., May 11, 2021 ...